Skip to main content
Top
Published in: Diabetologia 7/2011

01-07-2011 | Article

Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study

Authors: A. L. Christman, K. Matsushita, R. F. Gottesman, T. Mosley, A. Alonso, J. Coresh, F. Hill-Briggs, A. R. Sharrett, E. Selvin

Published in: Diabetologia | Issue 7/2011

Login to get access

Abstract

Aims/hypothesis

This study aimed to examine the association between diabetes and hyperglycaemia—assessed by HbA1c—and change in cognitive function in persons with and without diabetes.

Methods

This was a prospective cohort study of 8,442 non-diabetic and 516 diabetic participants in the Atherosclerosis Risk in Communities (ARIC) study. We examined the association of baseline categories of HbA1c with 6 year change in three measures of cognition: the digit symbol substitution test (DSST); the delayed word recall test (DWRT); and the word fluency test (WFT). Our primary outcomes were the quintiles with the greatest annual cognitive decline for each test. Logistic regression models were adjusted for demographic (age, sex, race, field centre, education, income), lifestyle (smoking, drinking) and metabolic (adiposity, blood pressure, cholesterol) factors.

Results

The mean age was 56 years. Women accounted for 56% of the study population and 21% of the study population were black. The mean HbA1c was 5.7% overall: 8.5% in persons with and 5.5% in persons without diabetes. In adjusted logistic regression models, diagnosed diabetes was associated with cognitive decline on the DSST (OR 1.42, 95% CI 1.14–1.75, p = 0.002), but HbA1c was not a significant independent predictor of cognitive decline when stratifying by diabetes diagnosis (diabetes, p trend = 0.320; no diabetes, p trend = 0.566). Trends were not significant for the DWRT or WFT in either the presence or the absence of diabetes.

Conclusions/interpretation

Hyperglycaemia, as measured by HbA1c, did not add predictive power beyond diabetes status for 6 year cognitive decline in this middle-aged population. Additional work is needed to identify the non-glycaemic factors by which diabetes may contribute to cognitive decline.
Literature
1.
go back to reference Biessels GJ, Staekenborg BE, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74PubMedCrossRef Biessels GJ, Staekenborg BE, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74PubMedCrossRef
2.
go back to reference Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48:2460–2469PubMedCrossRef Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48:2460–2469PubMedCrossRef
3.
go back to reference Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J (2009) Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 80:1194–1201PubMedCrossRef Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J (2009) Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 80:1194–1201PubMedCrossRef
4.
go back to reference Knopman DS, Mosley TH, Catellier DJ, Coker LH (2009) Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement 5:207–214PubMedCrossRef Knopman DS, Mosley TH, Catellier DJ, Coker LH (2009) Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement 5:207–214PubMedCrossRef
5.
go back to reference Folsom AR, Rasmussen ML, Chambless LE et al (1999) Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 22:1077–1083PubMedCrossRef Folsom AR, Rasmussen ML, Chambless LE et al (1999) Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 22:1077–1083PubMedCrossRef
6.
go back to reference Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR (2005) Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 4:821–826PubMedCrossRef Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR (2005) Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 4:821–826PubMedCrossRef
7.
go back to reference Association AD (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69CrossRef Association AD (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69CrossRef
8.
go back to reference Levitan EB, Song Y, Ford ES, Liu S (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164:2147–2155PubMedCrossRef Levitan EB, Song Y, Ford ES, Liu S (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164:2147–2155PubMedCrossRef
9.
go back to reference Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800–811PubMedCrossRef Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800–811PubMedCrossRef
10.
go back to reference Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E (2006) Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 10:293–295PubMed Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E (2006) Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 10:293–295PubMed
11.
go back to reference Selvin E, Coresh J, Zhu H, Folsom AR, Steffes MW (2010) Measurement of glycated hemoglobin from stored whole blood samples in the Atherosclerosis Risk in Communities study. J Diabetes 2:118–124PubMedCrossRef Selvin E, Coresh J, Zhu H, Folsom AR, Steffes MW (2010) Measurement of glycated hemoglobin from stored whole blood samples in the Atherosclerosis Risk in Communities study. J Diabetes 2:118–124PubMedCrossRef
12.
go back to reference Wechsler D (1981) Wechsler Adult Intelligence Scale-Revised Manual. Psychological Corp, New York Wechsler D (1981) Wechsler Adult Intelligence Scale-Revised Manual. Psychological Corp, New York
13.
go back to reference Knopman DS, Ryberg S (1989) A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol 46:141–145PubMed Knopman DS, Ryberg S (1989) A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol 46:141–145PubMed
14.
go back to reference Benton AL, Hamsher K (1989) Multilingual aphasia examination, 2nd edn. AJA Associates, Iowa City Benton AL, Hamsher K (1989) Multilingual aphasia examination, 2nd edn. AJA Associates, Iowa City
15.
go back to reference (2009) Stata Statistical Software: Release 11. StataCorp, College Station, TX (2009) Stata Statistical Software: Release 11. StataCorp, College Station, TX
16.
go back to reference Euser SM, Sattar N, Witteman JC et al (2010) A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes 59:1601–1607PubMedCrossRef Euser SM, Sattar N, Witteman JC et al (2010) A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes 59:1601–1607PubMedCrossRef
17.
go back to reference Knopman D, Boland LL, Mosley T et al (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56:42–48PubMed Knopman D, Boland LL, Mosley T et al (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56:42–48PubMed
18.
go back to reference van den Berg E, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, Biessels GJ (2010) A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 53:58–65PubMedCrossRef van den Berg E, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, Biessels GJ (2010) A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 53:58–65PubMedCrossRef
19.
go back to reference van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ (2009) Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta 1792:470–481PubMed van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ (2009) Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta 1792:470–481PubMed
20.
go back to reference Cukierman-Yaffe T, Gerstein HC, Williamson JD et al (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32:221–226PubMedCrossRef Cukierman-Yaffe T, Gerstein HC, Williamson JD et al (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32:221–226PubMedCrossRef
21.
go back to reference Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J (2010) Performance of glycated hemoglobin for the classification and prediction of diabetes. Diabetes Care 34:84–89PubMedCrossRef Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J (2010) Performance of glycated hemoglobin for the classification and prediction of diabetes. Diabetes Care 34:84–89PubMedCrossRef
22.
go back to reference Monnier VM, Sell DR, Genuth S (2005) Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 1043:567–581PubMedCrossRef Monnier VM, Sell DR, Genuth S (2005) Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 1043:567–581PubMedCrossRef
23.
go back to reference Peppa M, Vlassara H (2005) Advanced glycation end products and diabetic complications: a general overview. Hormones (Athens) 4:28–37 Peppa M, Vlassara H (2005) Advanced glycation end products and diabetic complications: a general overview. Hormones (Athens) 4:28–37
24.
go back to reference Qiu C, De Ronchi D, Fratiglioni L (2007) The epidemiology of the dementias: an update. Curr Opin Psychiatry 20:380–385PubMedCrossRef Qiu C, De Ronchi D, Fratiglioni L (2007) The epidemiology of the dementias: an update. Curr Opin Psychiatry 20:380–385PubMedCrossRef
Metadata
Title
Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study
Authors
A. L. Christman
K. Matsushita
R. F. Gottesman
T. Mosley
A. Alonso
J. Coresh
F. Hill-Briggs
A. R. Sharrett
E. Selvin
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2095-7

Other articles of this Issue 7/2011

Diabetologia 7/2011 Go to the issue